
Epizyme EPZM
Quartalsbericht 2022-Q2
hinzugefügt 09.08.2022
Epizyme EV 2011-2025 | EPZM
EV Jährlich Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.31 M | 1.23 B | 1.87 B | 687 M | 888 M | 530 M | 202 M | 481 M | 455 M | 56.7 M | 54.7 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.87 B | 4.31 M | 587 M |
EV anderer Aktien in der Pharmaeinzelhändler
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
436 M | - | 1052.0 % | $ 415 M | ||
|
Alpine Immune Sciences
ALPN
|
363 M | - | - | $ 2.17 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
457 M | $ 4.76 | 2.03 % | $ 790 M | ||
|
Aclaris Therapeutics
ACRS
|
192 M | $ 3.39 | 0.89 % | $ 262 M | ||
|
AlloVir
ALVR
|
-64.1 M | - | 4.14 % | $ 49.1 M | ||
|
Acasti Pharma
ACST
|
24 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
2.15 B | - | -15.15 % | $ 60.3 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-1.05 M | - | -11.43 % | $ 502 K | ||
|
Aeglea BioTherapeutics
AGLE
|
725 M | - | - | $ 1.01 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | ||
|
Ascendis Pharma A/S
ASND
|
726 M | $ 212.95 | 1.33 % | $ 5 B | ||
|
Albireo Pharma
ALBO
|
417 M | - | -0.23 % | $ 916 M | ||
|
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | ||
|
Aptorum Group Limited
APM
|
9.45 M | $ 1.28 | -3.76 % | $ 6.98 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-28.9 M | $ 3.39 | -0.88 % | $ 8.16 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | ||
|
AstraZeneca PLC
AZN
|
57.7 B | $ 89.67 | -0.69 % | $ 96.9 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
2 B | $ 25.58 | -1.24 % | $ 1.24 B | ||
|
Anika Therapeutics
ANIK
|
300 M | $ 9.58 | 0.95 % | $ 140 M | ||
|
Brickell Biotech
BBI
|
515 K | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
-9.74 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
115 M | - | -7.31 % | $ 87 M | ||
|
Biogen
BIIB
|
28.3 B | $ 174.16 | 0.96 % | $ 25.4 B | ||
|
Aytu BioScience
AYTU
|
-15.2 M | $ 2.32 | 1.84 % | $ 14.6 M | ||
|
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | ||
|
Baudax Bio
BXRX
|
29.8 M | - | 0.59 % | $ 63 K | ||
|
Avenue Therapeutics
ATXI
|
-1.23 M | - | -52.27 % | $ 4.45 M | ||
|
Benitec Biopharma
BNTC
|
461 M | $ 12.69 | -2.08 % | $ 522 M | ||
|
BioNTech SE
BNTX
|
-6.64 B | $ 95.45 | -0.58 % | $ 27.2 B | ||
|
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - | ||
|
ChromaDex Corporation
CDXC
|
408 M | - | -0.88 % | $ 598 M | ||
|
Axon Enterprise
AXON
|
41.5 B | $ 573.81 | -1.24 % | $ 43.5 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 0.28 | -2.62 % | $ 609 M | ||
|
Catalyst Biosciences
CBIO
|
38.1 M | $ 15.24 | -0.46 % | $ 1 B | ||
|
Checkpoint Therapeutics
CKPT
|
174 M | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
-6.94 M | - | -16.75 % | $ 25.8 M | ||
|
Clovis Oncology
CLVS
|
839 M | - | -7.23 % | $ 13 M | ||
|
BioVie
BIVI
|
-12.6 M | $ 1.49 | -1.57 % | $ 2.2 M | ||
|
Cortexyme
CRTX
|
132 M | - | -1.05 % | $ 67.1 M | ||
|
Celldex Therapeutics
CLDX
|
18.3 M | $ 27.81 | -0.47 % | $ 1.79 M | ||
|
Cellectar Biosciences
CLRB
|
60.8 M | $ 3.7 | -2.08 % | $ 45.2 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
1.24 B | - | - | $ 2.18 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
10.2 B | $ 11.52 | 0.7 % | $ 745 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
18.7 M | - | -5.68 % | $ 8.28 M | ||
|
Acer Therapeutics
ACER
|
38.2 M | - | 2.71 % | $ 14 M | ||
|
Enochian Biosciences
ENOB
|
145 M | - | - | $ 40.5 M | ||
|
Cerus Corporation
CERS
|
425 M | $ 2.23 | 3.49 % | $ 412 M | ||
|
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K |